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ABSTRACT
Tudor domain containing protein 9 (TDRD9) is a RNA helicase normally expressed 
in the germline, where it is involved in the biosynthesis of PIWI-interacting RNAs 
(piRNAs). Here, we show that TDRD9 is highly expressed in a subset of non-small cell 
lung carcinomas and derived cell lines by hypomethylation of its CpG island. Furthermore, 
TDRD9 expression is associated with poor prognosis in lung adenocarcinoma. We 
find that downregulation of TDRD9 expression in TDRD9-positive cell lines causes a 
decrease in cell proliferation, S-phase cell cycle arrest, and apoptosis. Transcriptomic 
analysis demonstrated that TDRD9 knockdown causes upregulation of cell cycle and 
DNA repair genes. We also observed that TDRD9 knockdown triggers activation of the 
catalytic subunit of the DNA dependent protein kinase (DNA-PKcs) and phosphorylation 
of H2A.X, which are indicative of an increase of DNA double strand breaks. TDRD9-
silenced cells also presented aberrant mitosis and abnormal-shaped nuclei indicating 
defects in chromosomal segregation. Finally, TDRD9 silencing caused hypersensitivity 
to the replication stress inducer aphidicolin, while overexpression of the protein 
increased resistance to the drug, suggesting that TDRD9 protects from replicative 
stress to TDRD9-positive tumor cells. Thus, our results place TDRD9 as a marker for 
prognosis and as a potential therapeutic target in a subset of lung carcinomas.
INTRODUCTION
Tudor domain containing protein 9 (TDRD9) is 
a putative ATP-dependent DEXH-box RNA helicase 
that contains a TUDOR domain [1, 2]. Under non-
pathological conditions, human TDRD9 is predominantly 
expressed in the germline. Mice Tdrd9 has been detected 
in spermatogonia, spermatocytes, spermatids in the testis 
and oocytes in the ovary [2]. Mammalian TDRD9 and 
the Drosophila homologue Spindle-E are involved in the 
process of biogenesis of a conserved class of small RNAs, 
called piRNA for their association with PIWI proteins 
[2–7]. piRNAs are implicated in transposon silencing at 
the transcriptional level in germ cells [5, 8–10], as recently 
reviewed in [11]. In fact, Tdrd9 is essential for silencing 
Line-1 retrotransposons in the mouse male germline [2]. 
Tdrd9 knockout mice display male sterility, probably 
as a consequence of massive Line-1 activation. Line-1 
DNA is hypomethylated in Tdrd9-/- mutants, indicating 
a connection between piRNA-mediated transcriptional 
silencing and DNA methylation [2, 9]. However, the 
specific role of TDRD9 in piRNA biogenesis and Line-
1 DNA methylation is unknown. TDRD9 interacts with 
MIWI2 (one of the mouse PIWI proteins) through its 
TUDOR domain and has been localized both in the nuclei 
and in the cytoplasm in germ cells-specific RNA structures 
called nuage [1, 2, 12]. 
Expression of germline-specific factors in tumor 
cells has received increased attention during the last years 
due to the fact that they can be ideal targets for cancer 
therapy [13–15]. Thus, the germline-restricted expression 
of these factors should, presumably, reduce side effects. 
As nothing was known about the role of TDRD9 in cancer, 
therefore we decided to search for abnormal TDRD9 
expression levels in different cancer databases and cell 
lines. Here we show that the TDRD9 gene is expressed 
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in about 15% of lung adenocarcinomas and 30% of skin 
melanoma tumors, but not in the normal tissues. The 
TDRD9 gene presents a CpG island in its 5´ region that is 
hypomethylated in spermatic tissues but hypermethylated 
in most human tissues where the gene is not expressed. 
We show that TDRD9-expressing cell lines and tumor 
samples display a strong hypomethylation of the TDRD9 
CpG island. Silencing of TDRD9 in lung cancer cell lines 
that express the gene causes a S-phase cell cycle arrest and 
increased DNA damage. Furthermore, TDRD9-deficient 
cells exhibit hypersensitivity to the replication stress 
inducer aphidicolin, while TDRD9 overexpression causes 
resistance to the drug, suggesting that TDRD9 plays a role 
in protection from replicative stress.
RESULTS
TDRD9 is highly expressed in lung 
adenocarcinoma and skin melanoma
As a first step to investigate a possible role of 
TDRD9 in cancer we explored publicly available cancer 
gene expression sets using the ONCOMINE database 
[16]. Analysis of TDRD9 expression in two sets of lung 
adenocarcinomas [17, 18] and skin melanomas [19, 20] 
showed that, in the cancer samples, values did not follow 
a normal (Gaussian) distribution (Shapiro-Wilk test P < 
0.00001) (Figure 1A), suggesting that the positive outlier 
values did not result from random variance. In fact, 
TDRD9 expression was significantly increased (more 
than 2-fold the median) in 13% (8 out of 59 samples) to 
15% (34 out of 225) of the analyzed lung adenocarcinoma 
samples (P < 0.0001 with respect to the level in normal 
lung tissue). Similarly, TDRD9 expression is increased in 
25% (6 out of 24) to 32% (13 out of 40) of the melanoma 
samples (P < 0.0001 with respect to the level in normal 
skin) (Figure 1A). We have also analyzed RNA-seq 
expression data from lung adenocarcinoma (TCGA-
LUAD) [21] and skin melanoma (TCGA-SKCM) [22] 
cohorts from The Cancer Genome Atlas (TCGA) through 
cBioPortal [23]. The majority of TCGA-LUAD tumors 
did not express, or expressed at very low levels, the 
TDRD9 transcript (TDRD9-negative tumors) (Figure 1B). 
However, 74 out of 491 tumors (15%) displayed high 
levels (≥ 5-fold over the median) of TDRD9 transcript 
(TDRD9-positive tumors). Similarly, most TCGA-SKCM 
samples either did not express TDRD9 or expressed it at 
very low levels. However, 149 of the 471 tumors (31%) 
expressed TDRD9 at high levels (≥ 5-fold over the median) 
(Figure 1C). Therefore, our analysis indicates that TDRD9 
is highly expressed in a subset of lung adenocarcinoma 
and skin melanoma tumors. Similar analysis of other types 
of tumors from TCGA showed that TDRD9 is expressed 
at high levels in a variable proportion of tumors, ranging 
from 1% in the case of colon cancer to 50% in acute 
myeloid tumors (AML) (Supplementary Figure 1).  
Kaplan-Meier survival curves revealed that 
TCGA-LUAD patients with TDRD9-positive tumors (n 
= 60) had a shorter survival as compared to those with 
TDRD9-negative tumors (n = 370), with median survivals 
of 32.7 versus 49.2 months, respectively (log-rank P = 
0.0022) (Figure 1D). In contrast, no significant survival 
differences were observed between TCGA-SKCM patients 
with positive or negative TDRD9 tumors (P = 0.1686) 
(Figure 1E). These data indicate that TDRD9 expression is 
a prognostic marker for a subset of lung adenocarcinoma.
Next we analyzed TDRD9 expression by 
conventional (RT-PCR) and quantitative reverse 
transcription-PCR (RT-qPCR) in lung adenocarcinoma 
(LA) cell lines and other non-small-cell lung carcinoma 
(NSCLC) cell lines. Four of the cell lines analyzed—the 
NSCLC lines NCI-H1299 and NCI-H1975, and the LA 
lines NCI-H1993 and NCI-H441—showed levels of 
TDRD9 mRNA similar to those in testis tissue (Figure 2A 
and 2B). Previous data from our lab indicated that TDRD9 
is also expressed in the cervix carcinoma cell line HeLa, 
therefore we also include this cell line in our assessment, 
as a positive control. In contrast, five cell lines—the LA 
lines A549, A427, and NCI-H1264, and the NSCLC lines 
NCI-H23 and NCI-H522—did not show significant levels 
of TDRD9 mRNA. Human lung tissue also had very low 
levels of TDRD9 expression (Figure 2A and 2B). These 
data confirm that TDRD9 is expressed in a subset of lung 
carcinoma cell lines.
The TDRD9 CpG island is hypomethylated in a 
subset of lung cancer
We next investigated the origin of the TDRD9 
expression in tumors. First, we verified that TDRD9 
expression was not correlated to the number of copies of 
the TDRD9 gene in the TCGA-LUAD and TCGA-SKCM 
tumors, ruling out gene amplification as the reason for 
high TDRD9 expression (Supplementary Figure 2).
The TDRD9 gene has a promoter-associated CpG 
island that expands from nucleotides –287 to +417 with 
respect to the transcription start site (TSS) (Figure 3A). 
Analysis of data from the Roadmap Consortium [24] 
by using the UCSC Genome Browser indicated that the 
TDRD9 CpG island is hypermethylated in most human 
organs (Supplementary Figure 3), including lung, 
consistent with the absence of expression of TDRD9 in 
these organs. However, the region was hypomethylated 
in spermatozoa, where TDRD9 is expressed. Then, we 
investigated the DNA methylation status of a region of 
the CpG island around the TSS (–234 to +109), in lung 
cancer cell lines with different levels of expression of 
TDRD9 using bisulphite genomic sequencing analyses 
of multiple clones (Figure 3B). The TDRD9 CpG 
island was hypermethylated in the cell lines that did not 
express TDRD9 (A549, A427, H522, H1264 and H23). 
However, a strong hypomethylation of the CpG island 
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was observed in the cell lines that expressed TDRD9 
(H1299, H1975, H1993 and H441). These data indicate 
that TDRD9 expression in LA and other types of NSCLC 
is associated to promoter CpG island hypomethylation. 
Consistently, treatment of H1264 and A549 cells that do 
not express TDRD9, and that display TDRD9 CpG island 
hypermethylation, with the DNA-demethylating agent 
5-aza-2´-deoxycytidine promoted TDRD9 expression 
(Figure 3C). Interestingly, TDRD9 expression was 
progressively lost in the H1264 cell population upon 
Figure 1: TDRD9 expression in lung adenocarcinoma and skin melanoma. (A) Analysis of TDRD9 expression in lung 
adenocarcinoma and skin melanoma. Data were obtained from the indicated sources through ONCOMINE. Statistical significance value 
for Student’s t-test is P < 0.0001. (B, C) RNA-seq expression data (RSEM normalized) from lung adenocarcinoma (TCGA-LUAD) (B) and 
skin melanoma (TCGA-SKCM) cohorts (C). (D, E) Kaplan-Meier survival plots for TCGA-LUAD patients (D) and TCGA-SKCM patients 
(E). P values were calculated by log-rank test. Data obtained from The Cancer Genome Atlas (TCGA). (B-E) TDRD9-positive tumors are 
shown in red; TDRD9-negative tumors are shown in blue.
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5-aza-2´-deoxycytidine removal, suggesting that signals 
that determine TDRD9 CpG island methylation are 
still present or, alternatively, that TDRD9 expression is 
deleterious for the proliferation in this cell line (Figure 
3D). 
Analyzing the TDRD9 methylation status in 
the TCGA-LUAD tumors revealed that TDRD9 
hypomethylation was associated with transcript 
overexpression (Spearman correlation test, ρ = –0.44, P 
< 0.00001, n = 429) (Supplementary Figure 4A). In fact, 
most (98%) of the tumor samples that did not express 
TDRD9 showed a high level of TDRD9 methylation 
(fraction of methylated cytosines > 0.5). In contrast, 
83% of the samples that expressed TDRD9 displayed a 
low level of TDRD9 methylation (fraction of methylated 
cytosines < 0.5). Similar results were obtained from 
TCGA-SKCM (ρ = –0.54, P < 0.00001, n = 458), where 
87% of the samples that expressed TDRD9 showed a 
low level of TDRD9 methylation (fraction of methylated 
cytosines < 0.5) (Supplementary Figure 4B). It has been 
shown that cancer CpG island hypomethylation often 
occurs in large genomic domains [25, 26]. Therefore, we 
analyzed the methylation status of the genes neighboring 
TDRD9 (Supplementary Figure 4C) by dividing the 
samples into two categories: TDRD9-positive and 
TDRD9-negative tumors, as defined in Figure 1B and 1C. 
While the level of DNA methylation of TDRD9 clearly 
decreased in TDRD9-positive tumors with respect to 
TDRD9-negative tumors (P < 0.0001), the methylation 
status of the genes neighboring TDRD9 was independent 
of the level of TDRD9 expression (Supplementary Figure 
4D and 4E). These data indicate that hypomethylation 
of TDRD9 is not linked to a general alteration of DNA 
methylation at the TDRD9 genomic region.
TDRD9 knockdown impairs proliferation in 
TDRD9-positive cell lines
Having observed the CpG island hypomethylation-
associated TDRD9 expression in a number of lung cancer 
cell lines (TDRD9-positive), we decided to investigate the 
role of TDRD9 in proliferation of these cells. Transfection 
of two different siRNAs that target the TDRD9 transcript 
(siTDRD9-1 and siTDRD9-2) significantly impaired 
Figure 2: TDRD9 is expressed in a subset of lung carcinoma cell lines. Several non-small-cell lung carcinoma (NSCLC) 
(NCI-H1299, NCI-H1975, NCI-H23, NCI-H522) and lung adenocarcinoma (LA) cell lines (NCI-H1993, NCI-H441, A549, A427, 
NCI-H1264) as well as HeLa cells were used to determine the expression of TDRD9 by conventional RT-PCR (A) or by RT-qPCR (B). 
Normal testis and lung tissues were used as positive and negative controls, respectively. M: 1 Kb Plus ladder. Values were normalized to 
GAPDH amplification. Data are the mean of at least n = 6 qPCR reactions from three independent experiments. Error bars represent ± SD 
values.
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cell proliferation in the H1299 and H1993 cell lines as 
compared to cells transfected with a control siRNA 
(Figure 4A and 4B; Supplementary Figure 5). As a control, 
we also verified that TDRD9 knockdown did not affect 
proliferation of the TDRD9-negative H1264 cell line 
(Figure 4B). We then analyzed the cell cycle of TDRD9-
depleted cells by flow-cytometry. TDRD9 knockdown 
provokes a reduction of the percentage of cells in G1 
phase, and a concomitant increase of the percentage of 
cells in S phase, in the TDRD9-positive cell lines H1299, 
H1993, and H441, but not in the TDRD9-negative H1264 
(Figure 4C), suggesting that the lower proliferation 
observed upon TDRD9 knockdown can be due to S phase 
arrest. In addition, siTDRD9-1 transfection caused a 3- to 
4-fold increase in the percentage of apoptotic cells after 72 
hours in the TDRD9-positive cell lines H1299 and H1993, 
but not in the TDRD9-negative cell line H1264 (Figure 
4D). Next we investigated the effect of lentiviral-mediated 
TDRD9 overexpression in cell proliferation of H1299, 
H1993 and H1264 cells. Overexpression of TDRD9 
caused a small but repetitive increase of proliferation in 
the TDRD9-positive cell line H1299 but had no effect in 
H1993 or in the TDRD9-negative H1264 (Supplementary 
Figure 6).
Characterization of transcriptional changes 
caused by TDRD9 knockdown
It has been shown that a complex between Tdrd9 and 
Miwi2 is involved in controlling Line-1 retrotransposase 
expression through piRNA-mediated hypermethylation in 
mouse germ cells [2]. In fact, PIWIL4 gene (the human 
orthologue of Miwi2) was expressed in several of the 
cell lines analyzed (Supplementary Figure 7A). Then, we 
determined the level of expression of the LINE-1 transcript 
in cell lines expressing or not expressing TDRD9 and 
PIWIL4. No correlation was present between TDRD9 and/
or PIWIL4 expression and the level of expression of the 
LINE-1 transcript (Supplementary Figure 7B and C). We 
next showed that downregulation of TDRD9 expression 
in TDRD9-positive and PIWIL4-positive cell lines did 
not affect the level of LINE-1 transcript (Supplementary 
Figure 7D). In conclusion, these data suggest that TDRD9 
does not control LINE-1 transcript expression in lung 
cancer cells.
To elucidate the transcriptional consequences of 
TDRD9 depletion in a TDRD9-positive cell line, we 
performed RNA expression profiling using Affymetrix 
DNA microarrays of H1993 cells transfected with 
siTDRD9-1, siTDRD9-2, or control siRNA. The two 
independent siRNAs against TDRD9 produced similar 
transcriptional changes with respect to the control siRNA 
(Pearson coefficient, r = 0.634, P < 0.0001) (Figure 5A). 
We selected 138 genes that were differentially expressed 
by both siRNAs (FDR < 0.01 and |lineal fold change| 
≥ 2 fold) of which 123 were up-regulated and 15 were 
down-regulated (Supplementary Table 1). Misregulated 
expression of nine genes upon reduction of TDRD9 
expression was confirmed by RT-qPCR (Figure 5B).
Biological process-Gene Ontology (BP-GO) 
analysis showed that several functional categories related 
to DNA repair, cell cycle, and mitotic cell division were 
strongly represented in the set of genes upregulated 
upon TDRD9 depletion (Figure 5C). RNA binding 
categories were also enriched when Molecular function-
GO enrichments were analyzed (Figure 5D). Pathways 
such as M phase (Bonferroni adjusted P = 0.0005), 
DNA replication (P = 0.0008), metabolism of RNA (P 
= 0.0013) and mitotic cell cycle (P = 0.0029) from the 
Pathway Commons database [27] were also enriched 
among the upregulated genes. Table 1 summarizes the 
effect of siTDRD9-1 or siTDRD9-2 on the transcript 
level of several cell cycle and DNA repair genes. Thus, 
genes whose expression normally increases at the S or 
G2/M phases, including those that encode subunits of 
the condensin and cohesin complexes (SMC1A, SMC2, 
SMC3 and ESCO1), centrosomal structural components 
(CEP250, CEP290, and CEP350), cell cycle regulators 
(CCND2, CDC27, and CDCA2), and the proliferation 
marker Ki-67 (MKI67), were upregulated upon TDRD9 
depletion. Supplementary Figure 8 shows that expression 
of cyclin D2 gene (CCND2) was also increased in other 
two lung cancer cell lines: H1299 and H441. In summary, 
transcriptomic analysis together with the cell cycle and 
proliferation data indicate that a decrease of TDRD9 
expression levels causes a cell cycle arrest in S phase. 
TDRD9 depletion causes accumulation of DNA 
damage
Expression of several genes involved in the DNA 
damage response was increased upon TDRD9 depletion 
(Table 1). In particular, the expression of PRKDC, which 
encodes the catalytic subunit of the DNA activated protein 
kinase (DNA-PKcs), was upregulated in TDRD9-silenced 
cells. DNA-PK is a central regulator of the response to 
double strand breaks that catalyzes the phosphorylation 
of histone H2A.X on Ser139 (γH2A.X). γH2A.X helps 
to recruit repair factors to double strand breaks [28] and 
coordinates the signal transduction cascades required 
for efficient repair [29]. Furthermore, DNA damage 
often blocks the progression of the DNA replication 
machinery and causes S-phase arrest, a phenotype 
observed in TDRD9-depleted cells. Therefore, we 
decided to investigate whether a reduction in the level 
of TDRD9 causes an increase of double-strand breaks 
(DSBs), as manifested by an increased level of activated 
DNA-PKcs (phospho-DNA-PKcs) and γH2A.X signals. 
As shown in Figure 6, siTDRD9-1-treated H1993 and 
H1299 cells presented increased levels of phospho-DNA-
PKcs, as determined by Western blotting (Figure 6A). 
Consistently, a strong increase in the γH2A.X signal 
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was also detected by both Western blotting (Figure 6B) 
and immunofluorescence (Figure 6C and 6D) in both 
cell lines. We also observed that TDRD9-depleted cells 
presented frequent aberrant mitosis and DNA bridges 
during anaphase (Figure 6E), indicative of a defective 
chromosomal segregation, which can originate from 
defects in DSB repair [30]. Finally, frequent abnormally-
shaped nuclei were also found (Figure 6F and 6G), which 
is also a hallmark of defective chromosomal segregation 
[31, 32]. Therefore, we hypothesized that TDRD9 
protects cells from DNA damage in TDRD9-positive 
lung carcinoma cells. Replicative stress is a common 
source of DNA damage in tumor cells [33]. In order to 
investigate whether TDRD9 is related to replicative 
stress, we have determined the sensitivity of TDRD9-
depleted cells to the replication stress inducer aphidicolin. 
Cells treated with siTDRD9.1 were hypersensitive to 
aphidicolin as compared to control cells (Figure 6H left 
panel). The non-linearity in the clonogenic survival plot 
of data from depleted-cells (Figure 6H, red) is indicative 
of the existence of a mixed population, probably as a 
consequence of differential silencing of TDRD9 in the 
siTDRD9-treated culture. In contrast, TDRD9-depleted 
cells were not hypersensitive to ionizing radiation 
(Figure 6H right panel). We next investigated whether an 
additional increase of the amount of TDRD9 protected 
cells from replicative stress caused by aphidiolin. 
Interestingly, overexpression of TDRD9 in the TDRD9-
positive H1299 and H1993 cell lines increased resistance 
to the drug (Figure 6I). However, TDRD9 overexpression 
did not have any significant effect in the TDRD9-negative 
cell line H1264 (Figure 6I). Taken together, our data 
suggest that TDRD9 plays a role in protecting a subset of 
lung cancer cells from replicative stress.
DISCUSSION
Here we show that the hypomethylation of the CpG 
island of TDRD9 leads to its expression in a subset of LA 
and NSCLC tumors and cell lines. We found that TDRD9 
expression is associated to poor prognosis for persons 
with LA. Importantly, knockdown of TDRD9 in TDRD9-
positive cell lines causes a decrease of cell proliferation, 
cell cycle arrest, increased DNA damage and apoptosis, 
indicating that TDRD9 could be a potential therapeutic 
target for TDRD9-positive tumors. 
TDRD9 has been previously identified as a putative 
Cancer/Testis antigen (CTA), in a microarray-based 
transcriptomic analysis of colorectal tumors [34]. CTAs 
are a group of tumor-associated antigens that are normally 
expressed in adult testis and often aberrantly expressed 
in several types of cancers [13–15]. Therefore, these 
data suggest that TDRD9 gene is also highly expressed 
in a subset of colorectal tumors. As we show here for 
TDRD9, CTA genes expression in tumors correlates with 
hypomethylation of their promoter-associated CpG islands 
Table 1: Genes upregulated upon silencing of TDRD9 in H1993 cells
Gene symbol Gene full name
Fold change Fold change
siTDRD9-1 siTDRD9-2
CEP250 Centrosomal protein 250kda 4.12 3.75
MKI67 Marker of proliferation Ki-67 4.10 3.18
PRKDC Protein kinase, DNA-activated, catalytic polypeptide, DNA-PKcs 4.02 4.13
ESCO1 Establishment of sister chromatid cohesion N-acetyltransferase 1 3.23 3.54
CEP350 Centrosomal protein 350kda 2.98 2.84
CDK11A Cyclin-dependent kinase 11A 2.91 3.21
SMC1A Structural maintenance of chromosomes 1A 2.89 3.00
BOD1L1 Biorientation of chromosomes in cell division 1-like 1 2.79 3.56
ATRX Alpha thalassemia/mental retardation syndrome X-linked 2.76 3.18
SMC3 Structural maintenance of chromosomes 3 2.74 2.95
CDC27 Cell division cycle 27 2.67 2.76
SMC2 Structural maintenance of chromosomes 2 2.54 2.39
ERCC6L2 Excision repair cross-complementation group 6-like 2 2.26 2.49
RIF1 Replication timing regulatory factor 1 2.15 2.28
CCND2 Cyclin D2 2.12 3.16
PARP1 Poly (ADP-ribose) polymerase 1 2.11 2.47
CDCA2 Cell division cycle associated 2 2.05 2.15
CEP290 Centrosomal protein 290kda 2.05 2.15
MAP4 Microtubule-associated protein 4 2.03 2.01
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[35]. Expression of testis-specific genes in tumor cells is 
often explained as a consequence of the dedifferentiation 
process that occurs during cell transformation [15]. 
Therefore, we hypothesize that TDRD9 hypomethylation 
and de-repression may be accompanied by de-repression 
of other CTA genes. However, expression of TDRD9 is 
not correlated with that of MAGEA1, MAGEA2, MAGEA3, 
or MAGEA4 (Supplementary Figure 9), which are CTA 
genes often expressed in lung cancer and melanomas [36]. 
In contrast, expression of MAGEA1-4 genes correlates 
positively. These data indicate that hypomethylation 
and de-repression of TDRD9 are not a consequence of a 
general de-differentiation and hypomethylation of all CTA 
genes. We have also shown that TDRD9 hypomethylation 
does not correlate with a widespread hypomethylation of 
the chromosomal region that contains the TDRD9 gene. 
Therefore, we speculate that hypomethylation of the 
TDRD9 CpG island is a specific tumor type-dependent 
event that is favored by the selective advantage conferred 
by the expression of TDRD9. Interestingly, forced 
hypomethylation and de-repression of TDRD9 by 5-aza-
2´-deoxycytidine treatment of TDRD9-negative cells, does 
not promote a stable de-repression of the gene, suggesting 
that TDRD9 expression does not confer a general selective 
advantage for all lung carcinoma tumor cells. 
Interestingly, SPN-E (the Drosophila homologue 
of TDRD9) and some other factors involved in piRNA 
metabolism, such as PIWI and AUB, are ectopically 
expressed in malignant brain tumors in Drosophila 
[37]. Several studies have reported aberrant and ectopic 
expression of PIWIL proteins in human tumors of different 
origins [38–41]. However, very little is known about the 
mechanism by which PIWIL proteins contribute to tumor 
cells growth. One obvious possibility is that PIWIL 
proteins control piRNA metabolism and transposon 
silencing in tumor cells; however, there is no evidence 
for this statement. Wang et al., have recently reported 
that ectopic expression of PIWIL4 in breast cancer does 
Figure 3: DNA methylation profile of the CpG island of TDRD9 promoter. (A) Schematic diagram of the CpG island of TDRD9 
promoter (-287 to +417 with respect to the transcription start site (TSS)). Amplified region for determination of DNA methylation (-234 to 
+109) is also shown. CpG pairs are represented by sticks. (B) Determination of DNA methylation by bisulfite conversion and sequencing 
of a region (-234 to +109 respect to the TSS) of the TDRD9 CpG island from different lung carcinoma cell lines. Open circles denote 
unmethylated CpGs, and filled circles represent methylated CpGs. Eight to fourteen independent clones of each sample were sequenced. 
(C) Relative mRNA expression levels of TDRD9 gene by RT-qPCR in TDRD9-negative lung carcinoma cell lines (H1264 and A549) after 
the treatment with 5-aza-2´-deoxycytidine for 72 hours. (D) Re-silencing of TDRD9 gene expression in the H1264 cell line following of 
5-aza-2´-deoxycytidine removal. Cells were treated with 5-aza-2´-deoxycytidine for 72 hours and then washed and cultured in the absence 
of the drug. Cells were passed 1:3 dilution every three days, and samples were taken at the indicated passage (P) for RNA isolation. Data 
are the mean of at least n = 6 qPCR reactions from three independent experiments. Error bars represent ± SD values.
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not affect significantly piRNA biosynthesis [41]. The 
strongest molecular phenotype of Tdrd9-/- mutant mice 
is the massive de-repression and hypomethylation of 
Line-1 [2]. In contrast, we have observed no correlation 
between either TDRD9 expression or TDRD9 depletion 
and the level of LINE-1 transcription. Taken together, 
these data suggest that the TDRD9 function in tumor 
cells is not related to control of LINE-1 expression. 
Therefore, how does TDRD9 expression favor cancer 
cell proliferation? We have found that TDRD9 silencing 
in TDRD9-positive cell lines caused a strong increase of 
γH2A.X, a chromatin marker of DSBs. TDRD9-depleted 
cells were not hypersensitive to γ-irradiation, suggesting 
that TDRD9 is not involved in the DSB repair process. 
However, TDRD9-depleted cells presented problems in 
S phase progression and exhibited hypersensitivity to 
the replication stress inducer aphidicolin. In addition, 
overexpression of TDRD9 protected from aphidicolin 
treatment in TDRD9-positive cell lines but not in the 
TDRD9-negative cell line H1264. Aphidicolin is a 
replication inhibitor that causes the replication folk to 
stall [42], activates the DNA replication checkpoint and 
increases DSBs [43]. It is well-established that replication 
stress is a hallmark of cancer and generates genetic 
instability [33]. We propose that TDRD9 plays a role in 
protecting a subset of lung carcinoma tumor cells from 
replicative stress. The mechanism by which TDRD9 
affects replicative stress is unknown. TDRD9 is a putative 
RNA helicase that contains a RNA binding domain and a 
TUDOR domain, the latter of which interacts with several 
RG and RGG motif-containing proteins (our unpublished 
results). Most RG/RGG motif proteins are involved in 
RNA biogenesis and processing [44].  In addition, several 
genes related to RNA metabolism were upregulated upon 
Figure 4: TDRD9 depletion impairs proliferation in TDRD9-positive cell lines. (A) Expression levels of TDRD9 in H1299 
and H1993 cell lines after the transfection with siRNA control or two different siRNAs against TDRD9. Data are the mean of at least n = 
6 qPCR reactions from three independent experiments. Error bars represent ± SD values. (B) Growth curve of TDRD9-depleted cell lines. 
A TDRD9-negative lung carcinoma cell line (H1264) was used as a control. Data are the average of four (H1299 and H1993) or three 
(H1264) independent experiments. Error bars represent standard deviation. Levels of TDRD9 mRNA during time points of the growth curve 
is shown in Supplementary Figure 5. (C) Flow cytometry of TDRD9-positive (H1299, H1993, and H441) or TDRD9-negative (H1264) 
lung carcinoma cell lines 72 hours after transfection of control siRNA or siRNA against TDRD9. Representative experiments are shown. 
(D) Level of apoptosis was determined 72 hours after transfection of control siRNA or siRNA against TDRD9, by measuring the percentage 
of cells containing a subG1 DNA content by flow cytometry. Data are the average of three independent experiments. Error bars represent ± 
SD values. A, B, D. Significance respect to the siControl was tested by using Student’s t-test. *P < 0.05; **P < 0.01.
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TDRD9 depletion, including DDX6, PAPOLA, DHX9, 
XRN1, SF3B1, FMR1, and ILF3 (see Supplementary 
Table 1). Many RNA metabolism factors affect genome 
stability [45], making it therefore possible that interactions 
created by the ectopic expression of TDRD9 in cancer 
cells contribute to alleviate replication stress. 
In conclusion, our data support that TDRD9 is not 
only a prognosis marker in lung cancer and potentially 
in other types of cancer (melanoma), but also a possible 
therapeutic target for TDRD9-positive tumors by 
inhibiting its RNA helicase enzymatic activity or by 
blocking its TUDOR domain with specific drugs.
MATERIALS AND METHODS
Cells, culture media, and treatments
The NCI-H1299, NCI-H1975, NCI-H1993, NCI-H441, 
NCI-H23, NCI-H1264, and NCI-H522 cell lines were grown 
in RPMI medium; the A549 and A427 cell lines were grown 
in DMEM/F12 medium; and the HeLa cell line was grown in 
DMEM medium. In all cases, media was supplemented with 
10% fetal bovine serum, 100 units/mL penicillin and 100 μg/
mL streptomycin. Cells were maintained at 37ºC in 5% CO2. 
Experiments were performed in less than 20 passages cells. 
Cell lines were obtained from the M. Esteller Laboratory 
(IDIBELL, Barcelona). Cells were periodically (ones per 
year) checked for Mycoplasma contamination and infected 
stocks were discarded. For in vivo demethylation assays cells 
were treated with 5-aza-2´-deoxycytidine (0.5 µM) for 72 
hours.
DNA methylation analyses
DNA methylation profiles were obtained by 
bisulphite genomic sequencing of at least eight clones. 
Genomic DNA was first modified with bisulphite-
mediated conversion of unmethylated cytosines to uracil 
and then purified using the EZ DNA Methylation-Gold 
Kit (ZYMO Research). The resulting modified DNA was 
Figure 5: Characterization of transcriptional changes caused by TDRD9 knockdown in the lung adenocarcinoma cell 
line H1993. (A) Correlation between the results obtained after knockdown of TDRD9 using two different siRNAs (Pearson coefficient, 
r = 0.634; P < 0.0001). (B) Effect of TDRD9 knockdown on the expression of the indicated genes. Expression levels of TDRD9 were 
determined as a control. mRNA levels were determined by RT-qPCR. Data are the mean of at least n = 6 qPCR reactions from three 
independent experiments. Error bars represent ± SD values. Significance respect to the siControl was tested by using Student’s t-test. 
*P < 0.05; **P < 0.01; ***P < 0.0001. (C) Biological process-GO categories enriched in genes upregulated after TDRD9 knockdown. (D) 
Molecular function–GO categories enriched in genes upregulated after TDRD9 knockdown. Bonferroni-corrected P values were -log10 
transformed.
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Figure 6: TDRD9 depletion causes DNA damage. (A, B) Effect of TDRD9 knockdown on the levels of P-DNA-PKcs protein (A) 
and γ-H2A.X (B) in H1993 and H1299 cell lines. Proteins levels were measured by Western blot using antibodies against the indicated 
proteins, 72 hours after the transfection of siRNA control (siControl) or siRNA against TDRD9 (siTDRD9-1). Protein levels were quantified 
by Odyssey imaging and plotted (lower panels). Intensity values were normalized to the loading control α-tubulin (A) or to the non-modified 
H2A.X (B). (C) Immunofluorescence of γH2A.X, 72 hours after the transfection of siControl or siTDRD9-1 in H1299 and H1993 cell 
lines. Nuclear DNA was counterstained with DAPI. (D) Quantification of γH2A.X-positive cells. Only nuclei with more than two foci were 
recorded. Data shown are means of three independent experiments. Error bars represent ± SD values. (E) Aberrant mitosis are observed in 
H1299 cells 72 hours after siTDRD9-1 transfection. Nuclei were stained with DAPI (blue). (F) Abnormally-shaped nuclei (arrow) observed 
in H1299 and H1993 cell lines 72 hours after siTDRD9-1 transfection. Nuclei were stained with DAPI (blue). C, E, F. Bars, 10 μm (G) 
Quantification of the percentage of abnormal nuclei observed in H1299 and H1993, 72 hours after siTDRD9-1 transfection as compared 
to cells transfected with siControl. (H) Survival curves (clonogenic assay) in response to increasing doses of aphidicolin (left panel) or 
ionizing radiation (right panel) in H1299 cells transfected with siControl or siTDRD9. (I) Growth inhibition by sublethal concentrations of 
aphidicolin of H1299, H1993 and H1264 cells transduced with lentiviral particles expressing TDRD9 (pHRSIN-DUAL-TDRD9) or control 
particles (pHRSIN-DUAL).  Student’s t-test *P < 0.01; ***P < 0.001; ***P < 0.0001.
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amplified by polymerase chain reaction (PCR) using the 
primers listed in Supplementary Table 2. The resulting 
amplified products were gel-purified, subcloned into the 
pGEM-T Vector Systems (Promega), and sequenced using 
the T7 and SP6 primers. 
TDRD9 silencing by siRNAs
For TDRD9 silencing, the different cell lines 
were transiently transfected with siRNAs using 
Oligofectamine (Invitrogen) for 72 hours. The 
following siRNA sequences were used: siTDRD9-1: 
5´-GCAACUUGGUAAACUCAUA-3´; siTDRD9-2: 
5´- AGCGCACCAUCCUUCUACUA-3´; and siControl: 
5´ -CGUACGCGGAAUACUUCGA-3´. 
Antibodies, western blotting, and 
immunofluorescence
Western blotting and immunofluorescence were 
performed as previously described [46]. The antibodies 
used were: rabbit polyclonal anti-phospho-DNA-PKcs 
(Ser2056) (4215, Cell Signaling), mouse monoclonal anti-
phospho-H2A.X (Ser139) (05-636, Millipore), and mouse 
monoclonal anti-alpha-Tubulin (T9026, Sigma-Aldrich). 
As secondary antibodies for Western blotting, goat IRDye 
680RD anti-mouse IgG (H+L) (926-68070, Li-COR 
Bioscience), and IRDye 800CW anti-rabbit IgG (H+L) 
(926-32211, Li-COR Bioscience) were used. Results were 
visualized using an Odyssey Infrared Imaging System (Li-
COR Bioscience). Alexa Fluor 488 goat anti-mouse IgG 
(A11001, Life Technologies) was used as a secondary 
antibody for immunofluorescence. 
Lentivirus production and transduction assays
For lentiviral production, 2 × 106 HEK293T 
cells were transfected with Fugene 6 (Promega) using 
7.5 μg of the transfer vectors pHRSIN-DUAL with 5 
and 2.5 μg of the packaging plasmids pCMVDR8.91 
and pVSVG, respectively. Lentiviruses were harvested 
72 h posttransfection, passed through a 0.45-μm filter 
and concentrated by ultracentrifugation at 100 000 × g 
for 90 min. Virus particles were resuspended in RPMI 
medium, snap frozen in liquid nitrogen and stored at 
−80 °C. Titers of pHRSIN-DUAL lentiviral particles were 
determined by FACS analysis of GFP-positive H1993 
infected cells. For ectopic expression of TDRD9 cells were 
infected with pHRSIN-DUAL or pHRSIN-DUAL-TDRD9 
lentivirus (MOI = 2), respectively. The dual-promoter 
lentivector pHRSIN-DUAL (also known as pHRSIN-
CSGWdINotI_pUb_Em) was kindly provided Mary K 
Collins (Windeyer Institute, London). For construction 
of the pHRSIN-DUAL-TDRD9 vector a cDNA encoding 
human TDRD9 was provided by RZPD, Berlin, Germany 
(I.M.A.G.E. Consortium (LLNL) cDNA clones) (RZPD 
clone ID:IMAGp998G0610753Q). BamHI restriction sites 
were inserted before the ATG of TDRD9 cDNA sequence 
using standard PCR techniques. A BamHI-NotI fragment 
containing the full length TDRD9 cDNA was cloned into 
pHRSIN-DUAL lentiviral vector previously linearized 
with BamHI and NotI.
Cell cycle and apoptosis analysis using flow 
cytometer
Cells were harvested, washed with PBS and 
resuspended in ice-cold PBS. Ethanol (70%) was added 
dropwise while vortexing at low speed, and cells were 
then fixed at 4°C for at least 1 hour. Cells were washed 
with PBS and treated with FACS buffer (250 μg/mL 
RNase A [Sigma-Aldrich], and 10 μg/mL propidium 
iodide diluted in PBS). Cells were incubated at 37°C for 
30 minutes and then analyzed using a FACSCalibur (BD). 
Apoptosis was determined by measuring the percentage of 
cells containing a subG1 DNA content.
Clonogenic survival and growth inhibition assays
For clonogenic survival assays, siRNA-treated cells 
were plated in triplicate on 10-cm dishes at clonal density 
(1000-2000 cells), allowed to adhere for 8 h, and damage 
treatments administered (aphidicolin or γ-irradiation). 
After 8–10 days of growth, plates were rinsed, fixed/
stained in 20% ethanol/4% crystal violet (w/v), rinsed 
in distilled water and colonies counted. Results were 
normalized respect to untreated conditions to adjust for 
plating efficiency and determine percentage survival.
For growth inhibition assays, 24 h after 
lentiviral transduction cells were treated with sublethal 
concentrations of aphidicolin (0.1 µM, 0.5 µM and 1 µM) 
and allowed to grow for additional 48 h. Then cells were 
counted and % of growth inhibition respect to untreated 
cells was calculated.
RNA extraction and mRNA quantification
Total RNA was isolated by using the RNeasy Kit 
(Qiagen) following manufacturer’s instructions, including 
DNase I digestion to avoid potential contaminations of 
DNA. The cDNA was generated from 100 ng of total 
RNA by using SuperScript First Strand Synthesis System 
(Invitrogen). cDNA (2 µl) solution was used as a template 
for conventional or real-time quantitative PCR (RT-PCR 
or RT-qPCR, respectively). Gene products were quantified 
by qPCR with the Applied Biosystems 7500 FAST Real-
Time PCR System, using Applied Biosystems Power 
SYBR Green Master Mix. Values were normalized to the 
expression of the human GAPDH housekeeping gene. 
Each experiment was performed at least in triplicate. 
Sequences of all oligonucleotides used are listed in 
Supplementary Table 2. 
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Microarray expression analysis
Three independent experiments of transfection of 
H1993 cells with siControl, siTDRD9-1 or siTDRD9-2 
siRNAs were performed. After 72 hours, total RNA was 
isolated from cells using RNeasy Mini Kit (Qiagen). Purity 
and quality of isolated RNA were assessed by RNA 6000 
Nano assay on a 2100 Bioanalyzer (Agilent Technologies, 
Santa 6 Clara, CA). RNA (100 ng) was used to produce 
end-labelled biotinylated ssDNA. Labeled ssDNA was 
hybridized to the GeneChip® PrimeView Gene Expression 
Array oligonucleotide microarray (Affymetrix, Santa 
Clara, CA) according to manufacturer’s recommendations. 
Arrays were scanned using the GeneChip Scanner 3000 
7G (Affymetrix), and raw data were extracted from 
the scanned images and analyzed with the Affymetrix 
GeneChip Command Console Software (Affymetrix). 
The raw array data were normalized using the Robust 
Multichip Average (RMA) method [47]. Fold-change 
and statistic parameters of siControl versus siTDRD9-1 
or siTDRD9-2 comparisons were performed using the 
LIMMA package [48] through oneChannelGUI [49]. 
Genes differentially expressed more than 2-fold (lineal 
change) and with FDR < 0.01 were selected. Genes that 
were differentially expressed with both siRNAs that target 
TDRD9 transcript were then selected for further analysis. 
Gene ontology functional categories were analyzed using 
DAVID [50] or WebGestalt [51]. The significance of the 
enrichment was computed using the hypergeometric test. 
Pathways enrichment of the Pathway Commons database 
was screened using the WebGestalt software packages. 
Bonferroni-adjusted P values of the hypergeometric 
test were used to determine enrichment significance. 
Microarray data are available from the GEO database 
(accession number GSE104151). 
Analysis of tumor datasets and statistics
Microarray gene expression data were obtained 
from ONCOMINE [16]. P values were calculated using 
a two-tailed Student´s t-test with a confidence interval of 
95% by using GraphPad Prism version 5.0. Shapiro-Wilk 
tests for normality were performed in http://scistatcalc.
blogspot.com.es/2013/10/shapiro-wilk-test-calculator.
html. RNA-seq expression data were obtained from The 
Cancer Genome Atlas (TCGA) (http://cancergenome.nih.
gov/). Clinical data of the cohorts for lung adenocarcinoma 
(TCGA-LUAD) [21] and skin melanoma (TCGA-SKCM) 
[22], and DNA methylation data, were obtained through 
cBioPortal (http://www.cbioportal.org/) [23]. Regression 
plots, and determination of Pearson coefficients were 
performed using Excel version 15.24. Survival plots 
and the log-rank test were performed using GraphPad 
Prism version 5.0. NIH Roadmap Epigenomics Mapping 
Consortium CpG methylation data were visualized by using 
the UCSC Genome Browser (http://genome.ucsc.edu/).
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